Donggu Bio & Pharmaceutical Invests Additional 1 Billion Won in Genome & Company

Signed CB Acquisition Agreement

"High Evaluation of Mid- to Long-Term Growth Potential"

Donggu Bio & Pharmaceutical announced on March 10 that it has signed a contract to acquire convertible bonds (CB) worth 1 billion won issued by Genome & Company.

Donggu Bio & Pharmaceutical previously invested approximately 3 billion won in Genome & Company in 2020 and later purchased an additional stake worth about 500 million won on the market, bringing its total investment to about 3.5 billion won to date. A representative from Donggu Bio & Pharmaceutical explained, "We decided to invest based on our high evaluation of Genome & Company's shift in R&D strategy and its mid- to long-term growth potential."

Genome & Company has focused its business on the development of early-stage immune-oncology microbiome therapeutics and research on discovering new targets. Recently, the company has expanded its R&D focus to include the development of antibody and antibody-drug conjugate (ADC) new drugs based on newly discovered targets identified internally.

Chairman Cho Yongjun of Donggu Bio & Pharmaceutical stated, "We plan to continue expanding strategic investments and partnership opportunities with bio-pharmaceutical companies that have global competitiveness in new drug development."

This content was produced with the assistance of AI translation services.